Wide Ranks

CLLS

Cellectis S.A.

2.13

Top Statistics
Market Cap 213 M Forward PE -2.80 Revenue Growth 998.00 %
Current Ratio 1.78 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -234.39 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -2.14 Enterprise / Revenue 4.00 Price To Sales Trailing12 Months 5.92
Profitability
Profit Margins -234.39 % Operating Margins -59.66 %
Balance Sheet
Total Cash 159 M Total Cash Per Share 1.59 Total Debt 89 M
Total Debt To Equity 69.44 Current Ratio 1.78 Book Value Per Share 1.29
All Measures
Short Ratio 168.00 % Message Board Id finmb_1216695 Fax 33 1 81 69 16 06
Shares Short Prior Month 346759 Return On Equity -0.8220 City Paris
Uuid a7dc8288-eba8-3f16-a312-d116920d6e16 Previous Close 2.14 First Trade Date Epoch Utc 1 B
Book Value 1.29 Beta 3.20 Total Debt 89 M
Volume 41225 Price To Book 1.65 Fifty Two Week Low 1.70
Total Cash Per Share 1.59 Total Revenue 36 M Shares Short Previous Month Date 1 B
Target Median Price 5.50 Max Age 86400 Sand P52 Week Change 0.3133
Operating Margins -59.66 % Target Mean Price 6.50 Net Income To Common -84478000
Short Percent Of Float 0.0018 Implied Shares Outstanding 102 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 77200 Average Volume10days 77200
Total Cash 159 M Next Fiscal Year End 1 B Revenue Per Share 0.4400
Held Percent Insiders 0.0387 Ebitda Margins -186.49 % Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 2.14
Target Low Price 3.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 1.95
Open 2.14 Free Cashflow -14382500 Dividend Yield 0.00 %
Return On Assets -0.1609 Time Zone Short Name EST Trailing Eps -1.16
Day Low 2.09 Address1 8, rue de la Croix Jarry Shares Outstanding 100 M
Price Hint 4 Target High Price 10.00 Website https://www.cellectis.com
52 Week Change -0.2852 Average Volume 52506 Forward Eps -0.7600
Recommendation Key none Compensation As Of Epoch Date 1 B Quick Ratio 112.90 %
Is_sp_500 False Regular Market Day High 2.15 Profit Margins -234.39 %
Debt To Equity 69.44 Fifty Two Week High 3.77 Day High 2.15
Shares Short 140456 Regular Market Open 2.14 Industry Key biotechnology
Earnings Growth 0.00 % Enterprise To Revenue 4.00 Revenue Growth 998.00 %
Shares Percent Shares Out 0.0014 Operating Cashflow 62 M Currency USD
Time Zone Full Name America/New_York Market Cap 213 M Is_nasdaq_100 False
Zip 75013 Quote Type EQUITY Industry Biotechnology
Long Name Cellectis S.A. Regular Market Day Low 2.09 Held Percent Institutions 0.1477
Current Price 2.13 Enterprise To Ebitda -2.14 Financial Currency USD
Current Ratio 1.78 Gross Margins 97.95 % Industry Disp Biotechnology
Number Of Analyst Opinions 6 Country France Float Shares 71 M
Two Hundred Day Average 2.33 Enterprise Value 143 M Price To Sales Trailing12 Months 5.92
Forward PE -2.80 Regular Market Volume 41225 Ebitda -67215000
Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
Cellectis S.

A.

, a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates.

The company is developing ALLO-715 and ALLO-605 for the treatment of multiple myeloma; ALLO-501 to treat large B-cell lymphoma; ALLO-316, an allogeneic engineered CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer.

It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin's lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.

The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics, Inc.; and joint research and collaboration, and investment agreement with AstraZeneca Holdings B.

V.

, as well as with AstraZeneca Ireland Limited.

Cellectis S.

A.

was founded in 1999 and is headquartered in Paris, France.